Clinical Trial Update: Molecular Mechanisms of Resistance and Sensitivity to Palbociclib Re-challenge in ER+ mBC [Phase 2]

View source ↗

Summary

Phase 2 clinical trial investigating molecular mechanisms of resistance and sensitivity to palbociclib re-challenge in ER-positive metastatic breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Palbociclib (palbociclib)

Snippet

Sponsor: MedSIR | Conditions: Metastatic Breast Cancer | Phase 2 | Status: COMPLETED